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Abstract
The 16th International Symposium on Cells of the Hepatic Sinusoid (ISCHS) took place in Florence, Italy on 22-24
September 2011. This symposium is a multidisciplinary meeting where new and important findings on the biology
of liver cells are presented and discussed.
Introduction
The 16th International Symposium on Cells of the
Hepatic Sinusoid (ISCHS) took place in Florence, Italy
on 22-24 September 2011 and was attended by 150
scientists from 16 Nations. This was the second meeting
of the newly formed International Society for Hepatic
Sinusoidal Research (ISHSR). The first meeting was
held last year in Pasadena, California (USA) and origi-
nates from the historical series of ISCHS, founded in
1977.
This year, the meeting showcased two state-of-the-art
lectures: Cholangiocytes and angiogenesis by Mario Straz-
zabosco (University of Milan-Bicocca, Milan, Italy and
Yale University Liver Center, New Haven, CT, USA), and
The functional role of chemokines in different chronic liver
diseases (CLD): focus on sinusoidal cells by Herman Was-
muth (University Hospital Aachen, Aachen, Germany).
Two tutorial lectures were given concerning ‘methods in
hepatology’ that covered new findings in the field of
microRNAs and hepatic stellate cells (HSC) presented by
Norifumi Kawada (Osaka City University, Osaka, Japan),
and methods for the study of neoangiogenesis in liver dis-
eases presented by David Semela (University Hospital
Basel, Basel, Switzerland).
The meeting was divided into seven thematic sessions:
(1) sinusoidal cells and the regulation of hepatic inflam-
mation, (2) nuclear receptors and liver cells, (3) sinusoi-
dal cells in alcoholic and non-alcoholic steatohepatitis
(ASH and NASH), (4) sinusoidal cells in metabolism,
portal hypertension, ischemia-reperfusion injury and
graft preservation, (5) sinusoidal cells, inflammation and
the microbiota, (6) nanotechnologies and advanced ther-
apeutics, and (7) role of sinusoidal cells (liver stroma) in
primary and metastatic liver cancer. All eight sessions
were covered by 18 lectures given by experts in a specific
topic followed by a total of 23 oral presentations pre-
sented by young investigators. Two selected poster over-
view sessions were dedicated to posters presented at the
meeting that represented excellent, well designed and
innovative topics related to all sessions covered during
this meeting. The symposium also honored one of our
colleagues who recently died. Massimo Pinzani and Gian-
luca Svegliati-Baroni gave a short commemoration of
Professor Marcos Rojkind (1935-2011), Professor of Bio-
chemistry, Molecular Biology and Pathology at George
Washington University Medical Center, Washington DC,
USA. This year, the work of Le Thi Thanh Thuy (Osaka
City University, Osaka, Japan) was awarded with the
Marco Foschi Prize for Research in Gastrointestinal
Oncology. This prize was assigned to a young researcher
for the best ISHSR 2011 oral presentation in the area of
oncology.
This meeting was sponsored by ISHSR and cospon-
sored by the European Association for the Study of the
Liver (EASL), American Association for the Study of
Liver Diseases (AASLD), the National Institutes of
Health, USA (NIAAA), and industrial support was given
by Pfizer, Merck & Co. and Intercept Pharmaceuticals.
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inflammation
The first invited lecture in this session was given by
P e r c yK n o l l e( I n s t i t u t eo fM o l e c u l a rM e d i c i n ea n d
Immunology, University of Bonn, Bonn, Germany),
introducing the important link between the innate
immune system and the adaptive immunity in the liver.
He introduced the unique immune functions to regulate
local and systemic immunity, with the engagement of
HSC and liver sinusoidal endothelial cells (LSEC) in the
regulation of the local immunity system. Percy demon-
strated that LSEC have immune cell characteristics
because they crossprime naïve CD8 T cells for tolerance
or immunity.
Nicholas Shackel (AW Morrow Gastroenterology and
Liver Centre, Camperdown, Australia), presented a
novel role of CD147, an abundant membrane receptor
glycoprotein ubiquitously expressed on hepatocytes and
liver leukocytes, in the context of intrahepatic inflamma-
tion. Liver injury was induced in murine models, that is
C57BL/6, BALB/c and CD147
-/- mice, with either thioa-
cetamide (TAA) or CCl4.T h ea u t h o r so ft h i sw o r k
demonstrated that liver leukocytes undergo CD45+
immune cell aggregates in progressive liver injury irre-
spective of cause of injury. This contributes directly to
the magnitude of injury with progressive inflammation-
associated liver injury.
Tumor necrosis factor a (TNFa)-converting enzyme
(TACE) is key to produce active TNFa, and is negatively
regulated by tissue inhibitor of metalloproteinases 3
(TIMP3), which is under the control of the silent infor-
mation regulator 1 (Sirt1). Nathalie Török (Division of
Gastroenterology and Hepatology, UC Davis, Sacra-
mento, CA, USA) demonstrated that advanced glycation
end products modulate proinflammatory activity by
inducing TACE activity in vitro and in vivo in a NASH
model. To assess the Sirt1/TIMP3/TACE axis in vivo,
mice were fed by normal chow, choline-supplemented,
L-amino acid (CSAA) or choline-deficient, L-amino acid
(CDAA) diets. The effect of TIMP3 on TACE activity
was quantified by injecting a TIMP3-expressing adeno-
viral vector. This resulted in a decrease in TACE and
profibrogenic activity.
The second invited lecture in this session, presented by
B i nG a o ,( N I A A A ,N I H ,B e t h e s d a ,M D ,U S A )a d d r e s s e d
the link between the innate immune system and the liver
tissue repair process. The liver relies on its strong innate
immune system to effectively and quickly defend against
potentially toxic agents, originating from the blood, with-
out launching harmful immune responses. This com-
prises enrichment of innate immune cells, removal of
waste molecules and immunologic elimination of micro-
organisms by liver endothelial cells and Kupffer cells.
Recent advances on the diverse roles of natural killer and
natural killer T cells in hepatocellular damage, liver fibro-
genesis, and liver regeneration were further discussed.
Additional and very relevant evidence that hepatitis C
virus (HCV) proteins can directly affect liver inflamma-
tion and fibrosis was presented by Soichi Kojima
(RIKEN ASI, Saitama, Japan). The authors of this work
demonstrated that HCV NS3 protease mimics trans-
forming growth factor (TGF)b2a n da c t i v a t e sT G F b sig-
n a l sv i at y p eIr e c e p t o r .T h er esults indicated that NS3
protease possesses the immunogenic and biological
activities of TGFb2. Antibodies that recognized the
three binding sites necessary for the interaction between
NS3 and TGFb receptor I blocked the TGFb activity
mimicked by NS3.
Session 2: nuclear receptors and liver cells
The first invited lecture in this session was given by
Michael Trauner (Medical University of Vienna, Vienna,
Austria), who addressed the functional role of the large
family of nuclear receptors (NRs) in liver and liver dis-
eases. As metabolic sensors, NRs are important in pro-
cesses that involve endobiotics and xenobiotics,
regulating the homeostasis of metabolism. Changes at
the transcriptional level lead to NR-deficient function
and can result in liver diseases acting on multiple cellu-
lar levels affecting transport, metabolism, inflammation
and fibrosis. Therefore, the search to target this NR led
to several molecular compounds to treat cholestasis and
non-alcoholic fatty liver disease (NAFLD).
In the second invited lecture Luciano Adorini (Inter-
cept Pharmaceuticals, New York, NY, USA) gave an over-
view of the working mechanism of bile acids that activate
two NRs: farnesoid × receptor (FXR) and the G-protein-
coupled receptor TGR5. These receptors are interesting
targets for a variety of diseases affecting liver, kidney and
intestine, in addition to metabolic diseases. Moreover,
new clinical data were shown on the use of the FXR ago-
nist INT-747, which has been successfully tested in clini-
cal studies, showing efficacy in patients with primary
biliary cirrhosis, type 2 diabetes and NAFLD.
The application of targeting a NR with specific ligands
was further demonstrated by V Balasubramaniyan (Insti-
tute of Hepatology, University College London, London,
UK). The activation of FXR by its agonist INT-747
restores hepatic endothelial nitric oxide synthase (NOS)
activity and lowers portal pressure in bile duct ligation
(BDL)-induced cirrhotic rats by modulating the dimethy-
larginine dimethylaminohydrolase 1 (DDAH)-asymmetric
dimethyarginine (ADMA) pathway. DDAH-2 expression
was reduced and this coincided with a significant lowering
of portal pressure. These data provide further evidence to
support the use of specific agonists such as INT-747 to
restore FXR hepatoprotective function in liver diseases
that are characterized by portal hypertension.
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specificity of the agonist INT-747 was shown by Matthew
Wright (Newcastle University, Newcastle, UK), who
demonstrated that INT-747 is also an activator of the
pregnane × receptor (PXR), another rather promiscuous
nuclear receptor that binds several bile acids. Administra-
tion of INT-747 to pxr
+/+ mice induced hepatic expression
of PXR-inducible cyp3a11 and cyp3a25 mRNAs. Hepatic
induction of cyp3a11 and cyp3a25 was abolished in mice
with a disrupted pxr gene. In this work, the authors
showed that the FXR agonist INT-747 also activates PXR
in both human and mouse.
Session 3: sinusoidal cells in alcoholic and non-alcoholic
steatohepatitis
As first invited lecturer, Isabelle Leclercq (Université
Catholique de Louvain, Brussels, Belgium) gave an excel-
lent overview of the very complex process of insulin
resistance (IR) and its impact on the liver and peripheral
tissues. Isabelle explained that IR is defined by the
impaired responsiveness of target organs to circulating
insulin translated as impaired inhibition of hepatic glu-
cose production, decreased peripheral glucose uptake,
leading to hyperglycemia, hyperinsulinemia and evolution
towards type 2 diabetes, and increased free fatty acids
released by adipose tissue.
Ariel Feldstein (University of California, San Diego, CA,
USA) addressed lipotoxicity and related effects on sinu-
soidal cells in the second invited lecture of this session.
NAFLD, the hepatic component of the metabolic syn-
drome, is a highly prevalent condition and associated
with increased morbidity and mortality. Studies have
uncovered a novel pathogenic role for adipose tissue
macrophages and Kupffer cells in the pathogenesis of
hepatic steatosis. This lecture showed that lipid partition-
ing and lipotoxicity have emerged as key pathogenic
mechanisms in liver damage and NASH development.
That HSC play a key role in alcoholic hepatitis (AH) was
proven by Silvia Affò (Liver Unit, IDIBAPS, Barcelona,
Spain). The investigator demonstrated that chemokine (C-
C motif) ligand 20 (CCL20) is a novel mediator of inflam-
mation and fibrosis in AH due to CCL20 expression in
HSC. The upregulation of hepatic CCL20 gene expression
and serum levels was specific for AH patients. By perform-
ing in vitro experiments in HSC, the authors demonstrated
that lipopolysaccharide (LPS), TNFa and interleukin 1b
(IL-1b) induced CCL20 gene expression and CCL20-
induced fibrogenic markers, wound healing and migration.
Wheatly Antony (University of Otago, Dunedin, New
Zealand) provided new insights into concanavalin A
(ConA)-induced hepatitis and the relative roles of gut
microflora, intestinal permeability, and Toll-like receptor
4 (TLR4). ConA administration was tested in TLR4
-/-,
C3H/HeN (LPS-sensitive) and C3H/HeJ (LPS-insensitive)
mice, and in C57/BL6 mice pretreated with the anti-
TLR4 monoclonal antibody (mAb), MTS510. Overall, the
results of this study indicate that ConA-induced hepatitis
is marked by increased intestinal permeability and
requires the presence of a functional TLR4 and of Gram-
negative bacteria or their products (LPS) in the gut.
ConA administration increased the percentage of TLR4-
positive CD3
+-T cells and Kupffer cells.
Information on the role of liver dendritic cells (DC) in
the pathogenesis of ethanol-induced steatosis in an
acute alcoholic liver injury (AALI) model in mice was
provided by Costica Aloman (Mount Sinai School of
Medicine, New York, USA). DC development is regu-
lated especially by Fms-like-3 tyrosine kinase ligand
(Flt3L) and its receptor Flt3. The authors induced AALI
in Flt3L-treated mice, in conventional dendritic cell
(cDC)-depleted CD11c-DTR mice that express the
diphtheria toxin receptor and in Flt3 knockout (Flt3-
KO) mice. The overall outcome of this study indicates a
key role for cDC-controlled development of steatosis
during AALI.
Kenichi Ikejima (Juntendo University School of Medi-
cine, Tokyo, Japan) demonstrated that mice depleted of
natural killer T (NKT) cells are more susceptible to diet-
ary-induced steatohepatitis. CD1d-KO animals, which lack
mature NKT cells, and wild-type (WT) mice were fed a
high-fat diet (HFD). Mice depleted of NKT cells appear to
be more susceptible to HFD-induced steatohepatitis, indi-
cating that hepatic NKT cells play a protective role against
development of dietary steatohepatitis. This involves a
downregulation of NKT cell-derived T helper 2 (Th2)
cytokines, a decreased synthesis of apolipoprotein B/very
low density lipoprotein (VLDL) and b-oxidation. There-
fore, NKT cells modulate hepatic lipid metabolism, thus
controlling the susceptibility to NASH.
Session 4: sinusoidal cells in metabolism, portal
hypertension, ischemia-reperfusion injury and graft
preservation
The first invited lecture in this session was given by Bard
Smedsrod (University of Tromsø, Tromsø, Norway)
describing the sinusoidal endothelial cells and metabolic
control. Bard demonstrated that LSEC play a central
metabolic role by taking up and catabolizing a large num-
ber of molecules. The cells are geared to efficient recep-
tor-mediated endocytosis and contain high lysosomal
enzyme activity, giving the cells a very high capacity to
catabolize endocytosed material. LSEC operate via a lar-
gely anaerobic metabolism because studies have demon-
strated that the cells release large amounts of lactate and
acetate, do not utilize glucose, carry few mitochondria,
and are located in a low oxygen environment.
As a result of the scarce information so far available
on the physiological function of human LSEC (hLSEC),
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set out to isolate and culture human LSEC. The author
studied the expression of endocytic receptors and other
phenotypic markers, and their ability to perform active
endocytosis via these receptors. hLSEC maintain pheno-
typic uniqueness, an appropriate profile for scavenger
receptors and endocytic function in culture, which was
preserved at early cell passages but reduced with later
passages, and this was accompanied by loss of specific
phenotypic LSEC markers.
Giusi Marrone (Hospital Clínic-IDIBAPS and CIBER-
EHD, Barcelona, Spain) investigated the role of the tran-
scription factor Kruppel-like factor 2 (KLF2), which
mediates hepatic endothelial protection conferred by sta-
tins. In this study the effect of statins on KLF2 functions
within the liver was investigated. Hepatic endothelial cells
were treated with different statins, in the presence of the
inhibitor mevalonate, under static or controlled shear
stress conditions. Statin treatment induced systemic or
liver endothelial KLF2 upregulation, which was inhibited
by mevalonate, and this was confirmed by in vivo experi-
ments. These data reinforce the therapeutic potential of
these drugs for liver diseases.
The second invited lecturer, Maurizio Parola (Experi-
mental Medicine and Oncology, University of Torino,
Turin, Italy) addressed hypoxia-dependent and indepen-
dent angiogenesis. Maurizio explained that hepatic angio-
genesis is involved in the progression of experimental and
clinical CLD and is believed to favor fibrogenesis since
experimental antiangiogenic strategies can effectively
block or attenuate fibrosis. Although hypoxia and
hypoxia-related mechanisms are key in mediating hepatic
angiogenesis in CLD, hypoxia-independent angiogenesis
also plays a significant role with a major involvement of
redox reactions and reactive oxygen species. Hepatic myo-
fibroblasts have emerged as a putative critical crossroads
between hypoxia-dependent and independent angiogenesis
because of their dual role as profibrogenic and proangio-
genic cells.
Jonel Trebicka (University of Bonn, Bonn, Germany)
reported that statins induce senescence in activated HSC
and interfere with angiogenesis in liver cirrhosis and portal
hypertension. In this study cirrhosis was induced by BDL
and CCl4 intoxication and portal hypertension was
induced by partial portal vein ligation. Results show that
statin therapy is beneficial in liver cirrhosis because it
decreases portal pressure, induces senescence in activated
HSC, decreases collateral formation, and activates hedge-
hog signaling in vascular smooth muscle cells (VSMC).
The author notes that statins might aggravate collateral
formation and even increases portal pressure in non-cir-
rhotic portal hypertension.
Chiara Busletta (University of Torino, Turin, Italy)
investigated the effect of hypoxia and oncostatin M (OSM)
on human mesenchymal stem cells (hMSC) and found
that both conditions exert motogenic stimulus on profi-
brogenic cells through a biphasic mechanism. This
mechanism is characterized by a first phase switched on
by rapid generation of reactive oxygen species (ROS),
whereas late migration is sustained by hypoxia-inducible
factor 1 (HIF-1)-dependent expression and release of vas-
cular epithelial growth factor (VEGF). OSM operates
through mechanisms homologous to those elicited by
hypoxia. Hypoxia-dependent and OSM-dependent migra-
tion were abolished by rotenone or apocynin, indicating
mitochondria or nicotinamide adenine dinucleotide phos-
phate (NADPH) as a source of ROS, respectively.
Session 5: sinusoidal cells, inflammation and the
microbiota
The invited lecture of this session was given by Gian-
luca Svegliati-Baroni (Università Politecnica delle
Marche, Ancona, Italy), addressing the microbiota in
steatohepatitis. Gianluca demonstrated the direct corre-
lation between gut microbiota and obesity as obese indi-
viduals have a different microbiota composition in
comparison to lean individuals. Furthermore, data
showed that small intestinal bacterial overgrowth and
consequent bacterial translocation are strictly related to
hepatic fibrogenesis and its degeneration. Toll-like
receptors and bacterial endotoxemia are involved in the
process of liver fibrogenesis.
Laura Dixon (Case Western Reserve, Cleveland, OH,
USA) reported that inflammasome-mediated caspase 1
activation in macrophages contributes to inflammation
and fibrosis in diet-induced steatohepatitis. The role and
cell specificity of caspase 1 activation in NASH was inves-
tigated. Caspase 1-KO mice were placed on a methionine
and choline deficient (MCD) diet. Caspase 1-associated
ASC (’apoptosis-associated speck-like protein containing a
C-terminal caspase recruitment domain’) was increased in
MCD-fed mice indicating the hepatic inflammasome acti-
vation. The author showed that caspase 1 expression,
F4/80 and Sirius red staining were significantly reduced in
clodronate-treated MCD-fed mice, and this confirmed the
coinvolvement of macrophages/Kupffer cells. These data
demonstrate that caspase 1 activation plays a role in
MCD-induced NASH.
Patricia Lalor (University of Birmingham, Birmingham,
U K )r e p o r t e dt h a tv a s c u l a ra dhesion protein 1 (VAP-1)
modulates glucose and lipid uptake in NAFLD. The
author showed an elevated level of VAP-1 in diseased
liver. VAP-1 substrates and inhibitors were used to per-
form standard ex vivo radiolabelled glucose and fatty
acid uptake assays, and showed that the VAP-1 semicar-
bazide-sensitive amine oxidase activity (SSAO) results in
enhanced hepatic lipid and glucose uptake and changes
in transporter expression. The author demonstrated that
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expression of glucose and lipid transporter proteins.
Session 6: sinusoidal cells in ASH and NASH
In this session the focus was on the effect of ethanol. The
first invited lecture was given by Sam Zakhari (NIAAA,
Bethesda, MD, USA), which introduced alcohol metabo-
lism in the hepatic sinusoid and its role in liver disease.
Ethanol metabolism increases ROS that leads to HSC
activation, and superoxide anion release in sinusoids acti-
vates Kupffer cells. Alcohol-induced inflammation results
in leukocyte trafficking through the sinusoids and the
rate of leukocyte recruitment and the nature of recruited
cells determines the severity of liver damage. Alcohol
produces pre-sinusoid venoconstriction, probably due to
prostaglandins produced from arachidonic acid metabo-
lism by cytochrome P450 2E1.
The second invited lecturer of this session, Gyongyi
Szabo (University of Massachusetts Medical School, Wal-
tham, MA, USA) discussed the effect of ethanol and sig-
naling modulation in liver non-parenchymal cells and
further emphasized on the role of TLR4-dependent sig-
naling pathways that mediate alcohol-induced liver stea-
tosis and inflammation. Kupffer cell sensitization is
mediated via alcohol-induced upregulation of micro-
RNA-155 that increases the message stability of TNFa.
There is activation of the inflammasome complex in liver
mononuclear cells in both ALD and NAFLD. These
results suggest that activation of innate immune signaling
extends to both TLR-induced and inflammasome-
mediated activation of the inflammatory cascade in ALD.
Hidekazu Tsukamoto (University of Southern California
School of Medicine, Los Angeles, CA, USA) discussed sec-
ond and multiple-hit models of ALD. Gene and environ-
mental interactions underlie chronic diseases including
ALD. The involvement of interactions among lifestyle fac-
tors i.e., viral hepatitis and alcohol, obesity and alcohol, or
triple combination, is becoming clinically apparent. They
induce synergistic effects on the genesis of fatty liver, stea-
tohepatitis, and liver cancer. Accordingly, animal models
that reflect these synergistic pathologic outcomes are
urgently needed for investigation of molecular mechan-
isms. Hide gave several examples of animal models where
molecular mechanisms had identified potential new thera-
peutic targets for synergistic alcohol-associated liver
diseases.
Fatima Teixeira-Clerc (INSERM, Paris, France) pro-
vided information on the mechanism by which the can-
nabinoid CB2 receptor exerts anti-inflammatory effects
in Kupffer cells during ALD. These data demonstrate
that the CB2 receptor displays beneficial effects on alco-
hol-induced inflammation by inducing heme oxygenase 1
(HO-1) in Kupffer cells, thereby limiting nuclear factor
B( N F B) activation and the proinflammatory M1
response. Alcohol-fed mice were treated with the CB2
agonist JWH-133 and showed increased expression of
HO-1 protein in Kupffer cells. HO-1 inhibition also pre-
vented the inhibitory effect of JWH-133 on LPS-induced
IL-6 and IL-1b expressions. These new data further sup-
port the CB2 receptor as a new anti-inflammatory target
in the management of ALD.
Michele Pritchard (Cleveland Clinic, OH, USA) identi-
fied the protective effects of adenosine signaling in etha-
nol-induced liver injury, which may be a useful anti-
inflammatory pathway to target and to attenuate the
pathophysiological effects of ethanol in the liver. Here, the
authors showed that adenosine, acting via the adenosine
2a receptor (A2AR), suppresses inflammatory cytokine
expression by Kupffer cells and that the anti-inflammatory
function of HO-1/globular adiponectin (gAcrp) also
involves the adenosine-mediated signaling pathway.
In vivo data showed that mice fed a Lieber-deCarli ethanol
diet treated with cobalt protoporphyrin (CoPP) or an
A2AR agonist increased both hepatic HO-1 and A2AR
mRNA expression in mice.
Session 7: nanotechnologies and advanced therapeutics
T h ef i r s tl e c t u r ew a sg i v e nb yM a r kK e s t e r( P e n nS t a t e
Hershey Cancer Institute, Hershey, PA, USA), which
introduced the clinical potential of sphingolipid-based
nanotherapeutics. Several examples were given concerning
the use of nanoconstructs to specifically target those genes
in a cell in a specific way in diseases. Stable, non-toxic
nanoscale formulations of ceramide have been engineered,
including nanoliposomes, nanocolloids and nanodendri-
mers. Mark demonstrated that these ‘nanosolutions’
reduce in vivo tumor burden in models of hepatocellular
carcinoma (HCC), and breast/pancreatic/melanoma can-
cer as well as leukemias. Nanotechnology has the potential
to ‘deliver’ the promise of ceramide-based pharmaceutics.
Klaas Poelstra (University of Groningen, Groningen, The
Netherlands) introduced a system of how to target drug
delivery, and focused on the HSC as key player during
liver fibrosis. Cell-specific drug delivery to HSC improves
their therapeutic efficacy, which is particularly important
for antifibrotic agents. Furthermore, drug targeting can
also be applied to examine the relative contribution of a
particular pathway, or cytokine, in disease progression.
Klaas showed new data of how interferon g (IFNg) and IL-
10 can be delivered to platelet-derived growth factor b
(PDGFb) receptors, which are highly expressed by HSC.
This leads to a significant improvement of their safety pro-
file and efficacy and opens up the possibility of a clinical
application.
Maria Lauda Tomasi (USC Research Center for Liver
Diseases, Los Angeles, CA, USA) reported that S-adeno-
sylmethionine (SAMe) regulates ubiquitin-conjugating
enzyme 9 (Ubc9) expression and sumoylation, with
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Methionine adenosyltransferase 1a-KO mice (Mat1a-
KO) are characterized by hepatic SAMe deficiency and
intragastric ethanol-fed mice are marked by an increased
susceptibility to steatosis and oxidative liver injury,
spontaneous development of steatohepatitis and HCC.
Ubc9 expression and sumoylation are increased when
SAMe levels fall and they contribute to many of the
abnormalities seen in both Mat1a-KO and alcohol-fed
mice. SAMe and its metabolite methylthioadenosine
decrease Ubc9 protein levels by lowering its phosphory-
lation status via inhibition of Cdc2 expression.
Session 8: new concepts of the role of the sinusoidal cells
(liver stroma) in primary and metastatic cancer
In the last session of this meeting, the first invited lecture
was given by Tania Roskams (University of Leuven, Leu-
ven, Belgium), who introduced the concept of liver cancer
cells and the stem cell niche. Hepatic progenitor cells are
capable of differentiating towards the biliary and the hepa-
tocytic lineage. An increase in the number of progenitor
cells and differentiation towards hepatocytes is a compo-
nent of all liver diseases. HCC show a range of hepatocel-
lular characteristics, but also progenitor cell features. HCC
expressing cytokeratin 19 (CK19), a potential marker for
progenitor cells, have a worse prognosis.
Samuele De Minicis (Università Politecnica delle
Marche, Ancona, Italy) demonstrated the role of fibrosis
as a cofactor in a new mouse model characterized by the
evolution of NASH to liver cancer. The authors created a
mouse model reproducing the pathological axis of human
NAFLD-NASH-cirrhosis-HCC and investigate the role of
fibrosis as a cofactor in promoting HCC. WT mice were
fed with a CDAA-defined diet and injected with a low
dose of CCl4 to stimulate fibrogenesis. After treatment,
95% of CDAA+/CCl4- mice revealed tumors and angio-
genic/tumor markers were upregulated. CCl4 in combina-
tion with a CDAA diet induces HCC formation in all
animals without changing fibrosis levels.
Another in vivo model was used by Le Thi Thanh Thuy
(Osaka City University, Osaka, Japan), which demon-
strated the promotion of liver and lung tumorigenesis in
diethylnitrosamine (DEN)-treated cytoglobin (Cygb)-defi-
cient mice. First, a Cygb-KO mouse was generated and
treated with N,N-diethylnitrosamine. All Cygb
+/- and
Cygb
-/- mice developed DEN-induced liver and lung
tumors whereas lung tumors were present only in Cygb-
deficient mice. Loss of Cygb was associated with
increased cancer cell proliferation, overexpression of
proinflammatory markers, and hepatic collagen accumu-
lation. Cygb-deficient mice also exhibited increased
nitrotyrosine formation and dysregulated expression of
cancer-related genes.
Taro Takami (Yamauchi University Hospital, Yamagu-
chi, Japan) reported that frequent autologous bone mar-
row cell infusions promote liver regeneration and suppress
tumor initiation in hepatocarcinogenic mice with liver cir-
rhosis. In this study a mouse model of hepatocarcinogen-
esis with liver cirrhosis (DEN/green fluorescent protein
(GFP)-CCl4 model) was developed and the kinetics of
hepatocarcinogenesis after bone marrow infusion (BMi)
was investigated. Foci and tumor in BMi liver showed
lower incidence and were smaller in number, while size
was almost equal. BMi-treated livers showed significantly
reduced liver fibrosis, a lower 8-OHdG levels and a higher
SOD activity. Therefore, the authors propose that frequent
autologous BMi might contribute to promote liver regen-
eration and suppress tumor initiation.
The second lecture was given by Matías Avila (Univer-
sity of Navarra, Pamplona, Spain) and discussed the new
molecular links between inflammation and liver cancer.
Inflammatory mediators and cytokines crosstalk with
growth factors and stimulate the survival and proliferation
of preneoplastic and transformed cells. For example, epi-
dermal growth factor receptor is activated in acute and
chronic liver injury and engages in extensive crosstalk
with growth factors, cytokines and inflammatory media-
tors. Moreover, its ligand amphiregulin (AR) is upregu-
lated in cirrhosis and HCC and conveys important survival
and proliferative signals to the transformed cells. Inhibi-
tion of the AR/epidermal growth factor receptor (EGFR)
signaling system may enhance the efficacy of targeted
therapies for HCC.
Bastian Höchst (University of Bonn, Bonn, Germany)
reported a new tumor immune suppression mediated by
LSEC. The observation that tumors progress in patients
with colorectal carcinoma despite the presence of tumor-
specific immune responses suggests that tumor develop-
ment leads to a number of immune suppressive mechan-
isms. By using different vaccination protocols, tumor
models and multicolor flow cytometry, the author showed
that LSEC are the dominant cells that take up carcinoem-
bryonic antigen (CEA), crosspresenting it to CD8+ T cells.
These tumor-specific T cells show a tolerance-associated
phenotype and are less effective in eliminating the CEA-
expressing MC-38 tumor cell-line.
Conclusions
The symposium again demonstrated that research on cells
of the hepatic sinusoid is flourishing. The two state-of-
the-art lectures, the invited lectures and the excellent
work presented as oral presentations or poster presenta-
tions reflects the continuing strength of hepatology
research in general. Overall, the most relevant aspect
emerging from this and the previous meeting of the
ISHSR (Pasadena 2010) is the increasing enthusiasm and
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Therefore, it is likely that research on the cells of hepatic
sinusoids will achieve greater robustness and international
recognition. The 17th ISHSR meeting will be held in
Osaka, Japan on 23-27 September 2013. Please check the
ISHSR website (http://www.ishsr.org) for further informa-
tion. See you in Osaka in 2013!
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